Financials data is unavailable for this security.
View more
Year on year Anika Therapeutics Inc had net income fall 456.34% from a loss of 14.86m to a larger loss of 82.67m despite a 6.67% increase in revenues from 156.24m to 166.66m.
| Gross margin | 62.70% |
|---|---|
| Net profit margin | -59.40% |
| Operating margin | -58.90% |
| Return on assets | -34.86% |
|---|---|
| Return on equity | -43.31% |
| Return on investment | -38.55% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Anika Therapeutics Inc fell by 13.46m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 1.79m. In addition the company used 5.43m on investing activities and also paid 6.32m in financing cash flows.
| Cash flow per share | -5.94 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 12.24 |
|---|---|
| Tangible book value per share | 11.51 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.34 |
|---|---|
| Quick ratio | 3.78 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
SmartText is unavailable
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -295.71 |
